Metastatic prostate cancer progressing despite androgen suppression: two main options
Prescrire International 22(136): 77
2013
ISSN/ISBN: 1167-7422 PMID: 23593700 Document Number: 671064
Document emailed within 1 workday
Related Documents
Gao, J.; Isaacs, J.T. 1998: Development of an androgen receptor-null model for identifying the initiation site for androgen stimulation of proliferation and suppression of programmed (apoptotic) death of PC-82 human prostate cancer cells Cancer Research 58(15): 3299-3306Roux, C. 2003: Osteoporosis due to androgen suppression therapy in men with prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(2 Suppl 1: 24-27
Matzkin, H.; Braf, Z. 1994: Complete androgen blockage in the treatment of metastatic prostate cancer Harefuah 126(5): 260-263
Jackson, K.M.; Frazier, M.C.; Harris, W.B. 2007: Suppression of androgen receptor expression by dibenzoylmethane as a therapeutic objective in advanced prostate cancer Anticancer Research 27(3b): 1483-1488
Johnke, R.M.; Edwards, J.M.; Evans, M.J.; Nangami, G.N.; Bakken, N.T.G.; Kilburn, J.M.; Lee, T.-K.; Allison, R.R.; Karlsson, U.L.; Arastu, H.H. 2009: Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression In Vivo 23(5): 827-833
Cerea, G.; Vaghi, M.; Ardizzoia, A.; Villa, S.; Bucovec, R.; Mengo, S.; Gardani, G.; Tancini, G.; Lissoni, P. 2003: Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations Anticancer Research 23(2c): 1951-1954
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Jarrard, D.F.; Kinoshita, H.; Shi, Y.; Sandefur, C.; Hoff, D.; Meisner, L.F.; Chang, C.; Herman, J.G.; Isaacs, W.B.; Nassif, N. 1998: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells Cancer Research 58(23): 5310-5314
Burk, K.; Gropp, C.; de Riese, W.; Löbenau, S. 1985: Experiences with polychemotherapy MAF (mitomycin C, adriablastine, 5-fluorouracil) in progressing metastasized prostate cancer Helvetica Chirurgica Acta 52(3-4): 601-603
Leewansangtong, S.; Soontrapa, S. 2003: The pattern of prostate-specific antigen responses following hormonal therapy in Thai men with bone metastatic prostate cancer Journal of the Medical Association of Thailand 86(9): 809-815
Kagebayashi, Y.; Ozono, S.; Takashima, K.; Yoshikawa, M.; Hayashi, Y.; Kaneko, Y.; Maruyama, Y.; Hirao, Y.; Okajima, E. 1997: Total androgen blockade for prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 43(3): 197-201
Mizokami, A.; Izumi, K.; Namiki, M. 2016: Role of adrenal androgen in prostate cancer Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 99-105
Roth, B.J. 1999: Androgen-independent prostate cancer: not so chemorefractory after all Seminars in Oncology 26(6 Suppl 18: 43-50
Beuzeboc, P.; Richaud, P. 2003: Androgen replacement therapy and prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(5 Suppl 2: 1276-1277
Kirby, R.S. 1996: Maximal androgen blockade (MAB) for the treatment of prostate cancer British Journal of Clinical Practice 50(5): 287